Tesamorelin is unusual among the “fat-loss” peptides because it is an actual approved drug (Egrifta) with real trial data — and because it targets one very specific kind of fat: visceral fat, the deep belly fat packed around your organs. In its trials it cut that visceral fat by roughly 15–18%.
But read the fine print. It was approved for a specific population (HIV-related fat accumulation), it does surprisingly little to the fat you can pinch or to the number on the scale, and the fat comes back when you stop. It is a visceral-fat tool, not a general weight-loss drug. Here is the honest picture.
What tesamorelin is
Tesamorelin is a stabilized version of growth-hormone-releasing hormone (GHRH) — a GHRH analog. Instead of being growth hormone, it prompts your own pituitary to release more of it, which in turn raises IGF-1. It was approved as the drug Egrifta to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, and its pivotal trial was published in the New England Journal of Medicine in 2007. For how it sits among the other GH-axis peptides, see CJC-1295 vs tesamorelin vs ipamorelin.
Visceral vs subcutaneous fat
This distinction is the whole story with tesamorelin. Your body stores fat in two main places: subcutaneous fat, the soft layer under the skin you can pinch, and visceral fat, the deep fat wrapped around the liver, intestines and other organs. Visceral fat is the metabolically dangerous kind — it is the fat most strongly linked to insulin resistance, fatty liver, and cardiovascular risk.
Tesamorelin’s claim to fame is that it preferentially shrinks visceral fat. That is why it was developed for a condition defined by deep abdominal fat accumulation, and why it interests researchers studying metabolic health rather than cosmetic slimming. It is also why it can reduce a hard, distended “GH belly” without doing much to the pinchable layer.
Tesamorelin goes after the fat you cannot pinch — the deep visceral fat around your organs — which is exactly the fat that matters most for metabolic health.Why it is a visceral-fat tool, not a scale-weight drug
What the trials showed
In the pivotal trials, tesamorelin reduced visceral adipose tissue by roughly 15–18% over about 26 weeks, while raising IGF-1 — the expected signature of more growth hormone. Later research also reported reductions in liver fat, which is meaningful because visceral and liver fat tend to travel together and both drive metabolic risk.
Two features stand out. First, the effect was specific: visceral fat dropped while subcutaneous fat and total body weight changed relatively little. Second, it was not durable — when treatment stopped, the visceral fat tended to return, which tells you the drug manages the fat rather than resetting it.
Does it work for ordinary belly fat?
This is where the marketing and the evidence part ways. The “belly fat” most people want to lose is a mix of subcutaneous and visceral fat, and tesamorelin was studied specifically in HIV-associated visceral fat accumulation — not in the general population, not for aesthetic slimming, and not as a weight-loss drug. Using it for an ordinary spare tyre is off-label and essentially unstudied.
And because it barely touches subcutaneous fat or scale weight, someone expecting to look dramatically leaner would likely be disappointed, even if their deep visceral fat improved. If your goal is overall weight loss, the GLP-1 drugs are a far better-studied route — see weight-loss injections in Canada. If your interest is specifically visceral and liver fat, that is the narrow lane where tesamorelin research lives. For the fatty-liver angle, see fatty liver in Canada.
Tesamorelin vs GLP-1 drugs
| Tesamorelin | GLP-1 drugs (e.g. semaglutide, tirzepatide) | |
|---|---|---|
| Mechanism | Raises your own GH/IGF-1 (GHRH analog) | Suppress appetite via gut hormones |
| Fat targeted | Mainly deep visceral fat | Overall body fat |
| Scale weight | Little change | Large reductions |
| Approved for | HIV-associated visceral fat | Obesity / type 2 diabetes |
| After stopping | Visceral fat returns | Weight tends to return |
Side effects
Because tesamorelin works by raising growth hormone, its side effects track GH excess: fluid retention and swelling, joint pain and stiffness, tingling or carpal-tunnel-type symptoms, and the potential to raise blood sugar — a real consideration for anyone with or at risk of diabetes. Injection-site reactions are common. See tesamorelin side effects for the fuller list.
Tesamorelin (Egrifta) is a prescription drug approved for a specific condition. It is not an approved general weight-loss or belly-fat treatment, and its effect on blood sugar makes medical supervision important. This article is research background, not advice or dosing guidance. TrueLabs sells tesamorelin for laboratory research only.
The research-compound angle
Tesamorelin is sold in the research-peptide market — at TrueLabs as Tesamorelin. As with every compound in this category, the research material is a raw substance for in vitro and laboratory study, not the approved Egrifta drug, and it carries no verified human dose, sterile formulation or regulatory oversight. The trial numbers above describe the pharmaceutical drug used under medical supervision. If your work is in the GH/IGF-1 axis or metabolic fat research, start with what is tesamorelin and how to read a peptide COA.
Tesamorelin belly-fat myths
“Myth: Tesamorelin is a weight-loss drug.”
It is not. It targets deep visceral fat and barely changes scale weight or subcutaneous fat. It was never developed or approved for general weight loss.
“Myth: It melts the fat you can pinch.”
No. Its effect is specific to visceral fat around the organs, not the subcutaneous layer under the skin.
“Myth: Results are permanent.”
Visceral fat tended to return after stopping in the trials. It manages the fat rather than resetting it.
“Myth: It is safe for anyone wanting a flatter stomach.”
It was studied in a specific HIV-related condition, can raise blood sugar, and is off-label and unstudied for ordinary belly fat.
For researchers
TrueLabs supplies Tesamorelin from $37, along with the other GH-axis compounds Ipamorelin from $40 and CJC-1295 from $31, in CAD for in vitro and laboratory research only. Before ordering, see how to read a peptide COA and the COA library.
FAQ
Tap a question to reveal the answer.
Does tesamorelin reduce belly fat?
It reduces deep visceral belly fat specifically — by roughly 15–18% in its trials — but does little to subcutaneous fat or scale weight. It is a visceral-fat tool, not a general slimming drug.
Is tesamorelin a weight-loss drug?
No. Total body weight changed little in trials. It was approved to cut visceral fat in HIV-associated lipodystrophy, not for weight loss.
How does tesamorelin work?
It is a GHRH analog: it prompts your own pituitary to release more growth hormone, raising IGF-1, which preferentially reduces visceral fat.
What is the difference between tesamorelin and GLP-1 drugs?
Tesamorelin raises GH/IGF-1 and targets deep visceral fat with little scale-weight change. GLP-1 drugs suppress appetite and cause large overall weight loss. Different mechanisms, different fat.
Does the fat come back after stopping?
Yes. Visceral fat tended to return once treatment stopped, so the effect is maintained rather than permanent.
What are the side effects?
They track growth-hormone excess: fluid retention, joint pain, tingling, injection-site reactions, and a potential rise in blood sugar, which matters for anyone with diabetes risk.
Can I use tesamorelin for regular belly fat?
It was studied only in HIV-associated visceral fat, not the general population, so such use is off-label and unstudied. It also barely affects the pinchable fat most people mean.
Is research tesamorelin the same as Egrifta?
No. Research tesamorelin (TrueLabs) is a raw compound for laboratory use, not the approved, dose-formulated drug, and carries no verified dose, formulation or oversight.
Related reading
- Best peptides for muscle growth
- CJC-1295 vs tesamorelin vs ipamorelin
- What is tesamorelin?
- Tesamorelin side effects
- Fatty liver in Canada
References
- Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV (tesamorelin). N Engl J Med. 2007;357:2359-2370. NEJM
- Stanley TL, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation. JAMA. 2014;312(4):380-389.
- EGRIFTA (tesamorelin) product label / prescribing information. Product label
- Health Canada. Advisory: unauthorized injectable peptide products, 2025.
This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.